Functional analysis of S100A14 as a new prognostic marker in lung cancer

Research Project

Project/Area Number	25860271
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Human pathology
Research Institution	Fukushima Medical University
Principal Investigator	Mizuko Tanaka 福島県立医科大学, 医学部, 助教 (40583638)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000) Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords	癌 / 肺癌 / 予後マーカー
Outline of Final Research Achievements	The aim of the study was to clarify the clinical significance and functional role of S100A14 in lung cancer.Immunohistochemical analysis of 219 non-small lung cancer cases showed that higher expression levels of these proteins were significantly associated with a poorer prognosis. In the human lung cancer cell lines QG56, S100A14 was localized on the cell membrane. A Boyden chamber assay showed that S100A14 knockdown substantially suppressed the invasive activity of cancer cells.Our findings suggest that S100A14 protein expression may be predictive biomarkers for poorer prognosis of non-small lung cancer patients.In addition, our findings indicate that this proteins can promote invasive activity of cancer cells.